Because FXR negatively regulates BA production and is deficient in MASH patients, global synthetic ligands of FXR, such as obeticholic acid, cilofexor, and tropifexor, have been developed to treat MASH.20 The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.